Table 1.
Baseline patients’ characteristics according to TP53 mutation status.
|
TP53-Mutated (N = 172) |
TP53 Wild-Type (N = 478) |
p-Value | |
|---|---|---|---|
| Age, median [IQR] | 52 [27–78] | 52 [51–87] | 0.284 |
| Histologic subtype | 0.016 | ||
| Ductal | 148 (86.0) | 366 (76.6) | |
| Lobular | 2 (1.2) | 23 (4.8) | |
| Others and Mixed | 22 (12.8) | 89 (18.6) | |
| Histologic grade | <0.001 | ||
| Grade III | 106 (61.6) | 138 (28.9) | |
| Grade I-II | 66 (38.4) | 340 (71.1) | |
| HR status # | <0.001 | ||
| Positive | 60 (35.3) | 261 (64.1) | |
| Negative | 110 (64.7) | 146 (35.9) | |
| HER2 status | <0.001 | ||
| Positive | 76 (44.2) | 128 (26.8) | |
| Negative | 96 (55.8) | 350 (73.2) | |
| Molecular subtype # | <0.001 | ||
| HR-positive/HER2-negative | 30 (17.6) | 209 (51.2) | |
| HER2-positive | 75 (44.1) | 113 (22.7) | |
| Triple-negative | 65 (38.2) | 86 (21.1) | |
| LVI # | <0.001 | ||
| Positive | 59 (34.5) | 83 (17.4) | |
| Negative | 112 (65.5) | 395 (82.6) | |
| Ki67 index (cutoff 20%) | <0.001 | ||
| High | 127 (73.8) | 150 (31.4) | |
| Low | 45 (26.2) | 328 (68.6) | |
| Neoadjuvant chemotherapy | 0.062 | ||
| Yes | 11 (6.4) | 15 (3.1) | |
| No | 161 (93.6) | 463 (96.9) | |
| T stage * | 0.035 | ||
| T1 | 69 (42.9) | 253 (54.6) | |
| T2 | 86 (53.4) | 195 (42.1) | |
| T3-4 | 6 (3.7) | 15 (3.2) | |
| N stage * | 0.826 | ||
| N0 | 97 (62.2) | 274 (60.8) | |
| N1 | 47 (30.1) | 135 (29.9) | |
| N2-3 | 12 (7.7) | 42 (9.3) | |
| Breast operation | 0.022 | ||
| BCS | 74 (43.0) | 159 (33.3) | |
| Mastectomy | 98 (57.0) | 319 (66.7) | |
| Axilla surgery | 0.152 | ||
| No approach | 6 (3.5) | 12 (2.5) | |
| SLNB | 135 (78.5) | 406 (84.9) | |
| ALND | 31 (18.0) | 60 (12.6) | |
| Adjuvant chemotherapy * | <0.001 | ||
| Yes | 140 (87.0) | 314 (67.8) | |
| No | 21 (13.0) | 149 (32.2) | |
| Post-operative radiotherapy | 0.007 | ||
| Yes | 96 (55.8) | 210 (43.9) | |
| No | 76 (44.2) | 268 (56.1) |
# Patients for whom accurate test values could not be confirmed were excluded. * Patients who received neoadjuvant chemotherapy or did not undergo surgery were excluded. Abbreviations, IQR; inter-quartile range, HR, hormone receptor, HER2; human epidermal growth factor receptor 2, LVI; lymphovascular invasion, BCS; breast-conserving surgery, SLNB; sentinel lymph node biopsy, ALND; axillary lymph node dissection.